GlycoNex Cash Flow Conversion Efficiency
GlycoNex cash flow conversion efficiency. Based on the latest financial reports, GlycoNex (4168) has a cash flow conversion efficiency ratio of -0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-17.29 Million ≈ $-544.86K USD) by net assets (NT$1.01 Billion ≈ $31.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GlycoNex (2017–2024)
Cash flow conversion efficiency of GlycoNex from 2017 to 2024. This chart illustrates how GlycoNex's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of GlycoNex for real-time trading data and today's change.
GlycoNex Cash Flow Conversion Ratio Explained
GlycoNex cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GlycoNex Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlycoNex ranked by their cash flow conversion efficiency. Also see GlycoNex (4168) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pinetree Capital Ltd
TO:PNP
|
-0.082x |
|
Cemtas Celik Makina Sanayi ve Ticaret AS
IS:CEMTS
|
-0.036x |
|
OFX Group Ltd
AU:OFX
|
0.923x |
|
Metrofile
JSE:MFL
|
0.237x |
|
Arena Group Holdings Inc
NYSE MKT:AREN
|
-2.718x |
|
Tonymoly Co Ltd
KO:214420
|
0.016x |
|
Oxford Square Capital Corp
NASDAQ:OXSQ
|
0.033x |
|
Eco World International Bhd
KLSE:5283
|
-0.054x |
Annual Cash Flow Conversion Efficiency for GlycoNex (2017–2024)
The table below shows the annual cash flow conversion efficiency of GlycoNex from 2017 to 2024. Review GlycoNex free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.05 Billion ≈ $32.97 Million |
NT$-221.97 Million ≈ $-6.99 Million |
-0.212x | -47.20% |
| 2023-12-31 | NT$1.28 Billion ≈ $40.21 Million |
NT$-183.92 Million ≈ $-5.79 Million |
-0.144x | -24.32% |
| 2022-12-31 | NT$1.45 Billion ≈ $45.54 Million |
NT$-167.55 Million ≈ $-5.28 Million |
-0.116x | -11.81% |
| 2021-12-31 | NT$1.36 Billion ≈ $42.81 Million |
NT$-140.86 Million ≈ $-4.44 Million |
-0.104x | -9.61% |
| 2020-12-31 | NT$1.54 Billion ≈ $48.51 Million |
NT$-145.59 Million ≈ $-4.59 Million |
-0.095x | +31.50% |
| 2019-12-31 | NT$1.30 Billion ≈ $40.98 Million |
NT$-179.58 Million ≈ $-5.66 Million |
-0.138x | -17.31% |
| 2018-12-31 | NT$1.53 Billion ≈ $48.28 Million |
NT$-180.34 Million ≈ $-5.68 Million |
-0.118x | -452.73% |
| 2017-12-31 | NT$1.84 Billion ≈ $58.01 Million |
NT$61.43 Million ≈ $1.94 Million |
0.033x | -- |
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more